Rebif interferon beta-1a: Additional Phase IIIb data

Additional data from the double-blind, international Phase IIIb IMPROVE trial in 180 patients showed that a new formulation of Rebif met the secondary endpoint of significantly reducing the number of combined unique active MRI lesions in patients originally randomized to placebo and switched to Rebif at week 16. Specifically, the mean number of combined unique active MRI lesions per crossover patient decreased from 2.31 on placebo at week 16 to 0.65 on Rebif at week 40 (p<0.001). ...